
REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab

10/09/2025 16:08:30

Main Information	
Primary registry identifying number LBCTR2021034775	Protocol number COMB157G23101
MOH registration number	
Study registered at the country of origin Yes	Study registered at the country of origin: Specify
Type of registration Prospective	Type of registration: Justify N/A
Date of registration in national regulatory agency	
Primary sponsor Novartis Pharma Services Inc.	Primary sponsor: Country of origin Novartis Pharmaceuticals
Date of registration in primary registry 21/11/2023	Date of registration in national regulatory agency
Public title An Open-label Study Evaluating Ofatumumab Treatment	Acronym
Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab	
Scientific title A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy	Acronym
Brief summary of the study: English	
The open label study to evaluate effectiveness of treatment with ofatumumab in patients transitioning from commonly used oral MS therapies - fingolimod or dimethyl fumarate, due to breakthrough disease.	
Brief summary of the study: Arabic	
للصاقة ذات مجموعة واحدة لتقييم فعاليّة العلاج بأوفاتوموماب والنتائج التي يفيد عنها المرضى المصابين بالتصلب اللويحي الانتكاسي الذين ينتقلون من العلاج بثنائي ميثيل الفومارات أو بفينغوليمود	دراسة تقدّميَّة متعددة المراكز مفتوحة ا
Health conditions/problem studied: Specify	
Relapsing Multiple Sclerosis	
Interventions: Specify	
Biological: Ofatumumab Patients in the ofatumumab will receive injections of ofatumumab provideo mg ofatumumab (50 mg/ml, 0.4 ml content) Other Name: OMB157	d in an autoinjector (AI) for subcutaneous administration containing 20



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Key inclusion and exclusion criteria: Inclusion criteria		
Inclusion Criteria:		
Diagnosis of multiple sclerosis (MS) Relapsing MS (RRMS or SPMS) course Subject transitioning from either fingolimod or dimethyl fumarate, following Breakthrough disease as evidence by clinical relapses or MRI EDSS score of 0 to 4	min 6 months treatment with either	drug
Key inclusion and exclusion criteria: Gender	Key inclusion and exclusion c	riteria: Specify gender
Both		
Key inclusion and exclusion criteria: Age minimum	Key inclusion and exclusion c	riteria: Age maximum
18	60	-
Key inclusion and exclusion criteria: Exclusion criteria		
Primary progressive MS or SPMS without disease activity Disease duration of more than 10 years since diagnosis Patients with an active chronic disease of the immune system other than M Patients at risk of developing or having reactivation of hepatitis Patients with active systemic infections or with neurological findings consis apply		ed inclusion/exclusion criteria may
Type of study		
Interventional		
Type of intervention	Type of intervention: Specify t	type
Pharmaceutical	N/A	
Trial scope	Trial scope: Specify scope	
Therapy	N/A	
Study design: Allocation	Study design: Masking	
Single Arm Study	Open (masking not used)	
Study design: Control	Study phase	
N/A	3	
Study design: Purpose	Study design: Specify purpose	٥
Treatment	N/A	•
Study design: Assignment	Study design: Specify assignr	nent
Single	N/A	
IMP has market authorization	IMP has market authorization:	Specify
Yes, Lebanon and Worldwide	USA, UK, UAE, KSA, Albania, A Singapore , Switzerland, Belgiur	Argentina, Australia, Canada, n, Netherlands, France, Lebanon
Name of IMP	Year of authorization	Month of authorization
Ofatumumab	2021	11
Type of IMP		
Immunological		
Pharmaceutical class		
Monoclonal antibodies		
Therapeutic indication		

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Therapeutic benefit	
potential efficacy of ofatumumab in patients with relapsing MS.	
Study model	Study model: Explain model
N/A	N/A
Study model: Specify model	
N/A	
Time perspective	Time perspective: Explain time perspective
N/A	N/A
Time perspective: Specify perspective	
N/A	
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention	Biospecimen description
Samples without DNA	Covance Central lab : Ambient and Frozen conditions
Target sample size	Actual enrollment target size
10	15
Date of first enrollment: Type	Date of first enrollment: Date
Actual	10/08/2021
Dete of study elecures Ture	Date of study elecures Date
Date of study closure: Type Actual	Date of study closure: Date 25/06/2025
Recruitment status Complete	Recruitment status: Specify
Date of completion 04/10/2022	
IPD sharing statement plan	IPD sharing statement description
Yes	Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical
	documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of
	scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with
	applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

 \sim



Additional data URL

https://clinicaltrials.gov/ct2/show/record/NCT04353492?

 $term = of a tumumab + treatment + effectiveness\& cond = relapsing + multiple + sclerosis + transitioning\& draw = 2\& rank = 1 \\ for all the sclerosis + transitioning\& draw = 1 \\ for all the sclerosis + transitioning\& draw = 2\& rank = 1 \\ for all the sclerosis + transitioning\& draw = 2\& rank = 1 \\ for all the sclerosis + transitioning\& draw = 2\& rank = 1 \\ for all the sclerosis + transitioning\& draw = 2\& rank = 1 \\ for all the sclerosis + transitioning\& draw = 1 \\ for all the sclerosis + transitioning\& draw = 1 \\ for all the sclerosis + tra$

Admin comments

Trial status

Approved

Secondary Identifying Numbers

Full name of issuing authority	Secondary identifying number	
NCT04353492	Clinical trials.gov	

Sources of Monetary or Material Support

Name

Novartis Pharma services Inc.

Secondary Sponsors	
Name	
NA	

Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Taghrid El Hajj	Beirut	Lebanon	961349400 8	taghridelhajj@gm ail.com	Rafik Hariri University Hospital
Scientific	Hind Khairallah	Sinelfil	Lebanon	01512002# 271	Hind.khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l
Public	Halim Abboud	Beirut	Lebanon	961353571 1	halimabboud@h otmail.com	Hotel Dieu De France
Public	Salam Koussa	Beirut	Lebanon	961372677 1	drkoussa@hotm ail.com	Lebanese Geitaoui Hospital
Public	Samia Khoury	Beirut	Lebanon	961135000 0#7422	sk88@aub.edu.lb	American University of Beirut Medical Center



Centers/Hospitals Involved in the Study			
Center/Hospital name	Name of principles investigator Princ speci		Ethical approval
Rafik Hariri University Hospital	Taghrid El Hajj	Neurology	Approved
Hotel Dieu De France	Halim Abboud	Neurology	Approved
Lebanese Hospital Geitaoui	Salam Koussa	Neurology	Approved
American University of Beirut Medical Center	Samia Khoury	Neurology	Approved

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Rafic Hariri University Hospital	02/12/2020	Rawan Yammout	rawan.yamout@crurhuh.com	018300000 ext 2037
Hotel Dieu de France	03/11/2020	Sami Richa	cue@usj.edu.lb	961421229
Hopital Libanais Getaoui Centre Hospitalier Universitaire	23/03/2021	Raja Chaftari	irb@hopital-libanais.com	961 1 590 000 # 8872 8859
American University of Beirut Medical Center	25/05/2021	Fuad Ziyadeh	fz05@aub.edu.lb	9611350000#5445



Countries of Recruitment
Name
Lebanon
Australia
Austria
Belgium
Bulgaria
Czech Republic
Germany
Greece
Hungary
Norway
Poland
Portugal
Russian Federation
Slovakia
Spain
Switzerland
Turkey
United States of America

Health Conditions or Problems Studied		
Condition Code Keyword		
Relapsing Multiple sclerosis	Multiple sclerosis (G35)	MS





Interventions		
Intervention	Description	Keyword
Informed Consent form , IMP administration , Visit assessment and schedule	Informed Consent form , IMP administration , Visit assessment and schedule	ICF, IMP

Primary Outcomes		
Name	Time Points	Measure
Annual Relapse Rate	96 weeks	number of confirmed relapses in a year calculated based on cumulative number of relapses by patient adjusted for time-in-study by patient

Key Secondary Outcomes		
Name	Time Points	Measure
Safety evaluation	96 weeks	Proportion of patients with adverse events, including injection related reactions, abnormal laboratory results or vital signs as well as proportion of patients discontinuing treatment due to insufficient effectiveness or safety





Trial Results Summary results Study results globally Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files